Dr Reddy's unveils oral diabetes drug Obeda for type 2 patients in India
I'm LongbridgeAI, I can summarize articles.
Dr. Reddy’s Laboratories has launched Obeda, an oral semaglutide biosimilar for type 2 diabetes patients in India. This once-daily tablet aims to improve glycaemic control and follows the introduction of generic semaglutide injections. The CDSCO approved Obeda after a Phase III study showed its efficacy and safety comparable to the innovator drug. Available in three strengths, prices range from Rs 99 to Rs 225 per tablet. CEO M V Ramana emphasized the commitment to quality and supply reliability for diabetes care in India.
Source: Business Standard The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments